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Background: For patients who present with synchronous colorectal carcinoma and colorectal liver
metastasis (CRLM), a reversed treatment sequence in which the CRLM are resected before the primary
carcinoma has been proposed (liver-first approach). The aim of the present study was to assess the
feasibility and outcome of this approach for synchronous CRLM.
Methods: Between 2005 and 2010, 22 patients were planned to undergo the liver-first approach.
Feasibility and outcomes were prospectively evaluated.
Results: Of the 22 patients planned to undergo the liver-first strategy, the approach was completed in
18 patients (81.8%). The main reason for treatment failure was disease progression. Patients who
completed treatment and patients who deviated from the protocol had a similar location of the primary
tumour, as well as comparable size, number and distribution of CRLM (all P > 0.05). Post-operative
morbidity and mortality were 27.3% and 0% following liver resection and 44.4% and 5.6% after colorectal
surgery, respectively. On an intention-to-treat-basis, overall 3-year survival was 41.1%. However, 37.5%
of patients who completed the treatment had developed recurrent disease at the time of the last
follow-up.
Conclusions: The liver-first approach is feasible in approximately four-fifths of patients and can be
performed with peri-operative mortality and morbidity similar to the traditional treatment paradigm.
Patients treated with this novel strategy derive a considerable overall-survival-benefit, although disease-
recurrence-rates remain relatively high, necessitating a multidisciplinary approach.
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Introduction
Up to one-fourth of patients who present with colorectal cancer
have concomitant colorectal liver metastasis (CRLM).1,2 Patients
with these synchronous CRLM are thought to have a worse prog-
nosis compared with patients with metachronous CRLM.3 While
surgical resection of CRLM is regarded the only potential for a
cure,4,5 the simultaneous presentation of primary and secondary
disease provides a unique chance in deciding the optimal therapy
sequence in these patients.
The classic approach for patients with synchronous CRLM
encompasses resection of the primary tumour, followed by
optional adjuvant chemotherapy and eventually succeeded by
liver surgery. Potential advantages of this approach are primary
tumour oriented and include prevention of local ingrowth, bowel
obstruction or bleeding from the colorectal carcinoma. However,
major disadvantages include progression of the CRLM beyond
resectability, especially after a delay in the treatment paradigm
owing to morbidity associated with the colorectal surgery.
Moreover, in case of chemotherapy, serious hepatoxicity can
occur6,7 or the hepatic lesions can disappear.8 While some authors
have therefore supported a simultaneous resection of the
primary tumour and concurrent liver disease,9–11 others advocated
a staged approach in which the liver is operated on before the
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primary tumour and increasingly frequently preceded by induc-
tion chemotherapy.12–14 Particularly for rectal primaries, the latter
approach is regarded as more natural as the post-radiation
required waiting period offers ample time for performance of a
liver resection. Additional rationale for this reversed sequence of
therapy is that CRLM are the main cause of death and that it is
therefore important to eliminate these lesions first. With a liver-
first approach, the treatment of the CRLM is by no means inter-
rupted by possible complications after resection of the primary
tumour. A concurrent advantage could be that administration of
pre-operative chemotherapy provides a chance to evaluate a
response and thereby define the tumour biology of the CRLM.
Moreover this strategy provides a certain window during which
possibly latently present extrahepatic metastases have a chance to
declare themselves.15,16
Currently, there are very little data available regarding the liver-
first approach.12,14,17,18 Therefore, the aim of the present study was
to describe the experience with the liver-first approach in a ter-
tiary referral centre. Moreover, we sought to not only examine the
feasibility and short-term outcomes after the liver-first approach,
but also to assess the influence of this sequence in therapy on the
oncological outcome.
Methods
Prospectively collected data on patients who underwent liver
surgery from 1st January 2005 to 31st December 2010 were
queried from the hepatectomy databases at a large hepatobiliary
centre (Maastricht University Medical Centre). All patients with
synchronous CRLM were identified. In 22 of these patients, a
liver-first approach was planned and these patients are the scope
of the present study.
During pre-operative assessment, patients were deemed resec-
table only if a resection with negative margins was expected for all
known disease, both intra- and extrahepatic. Moreover, only
patients in whom an adequate future liver remnant was antici-
pated on computed tomography (CT) volumetric analysis were
considered candidates for hepatic resection.19,20 Furthermore, the
future liver remnant had to incorporate a minimum of two adja-
cent segments with sufficient vascular in- and outflow and
adequate biliary drainage to be regarded suitable for resection.5,21
In short, after patients were diagnosed with synchronous
CRLM, they were referred to our tertiary referral centre (coordi-
nated by the Surgical Oncologic Network of Limburg) and were
subsequently presented and discussed in a multi-disciplinary
oncology meeting, during which their treatment strategy was
established. Specifically, all patients with rectal cancer underwent
standard locoregional staging with standard T2-weighted mag-
netic resonance imaging (MRI) which was in some cases extended
with an additional gadofosveset-enhanced imaging sequence for
lymph node staging, in accordance with our institutional protocol
described previously.22 For patients with a primary tumour
located in the colon, pre-operative staging was generally ascer-
tained using a computed tomography (CT) scan. In general, all
patients who were diagnosed with a rectal tumour, based on these
imaging modalities, received pre-operative radiation therapy con-
sisting of either a short course (5 ¥ 5 Gy) of radiation or a long
course of 28 fractions of 1.8 Gy radiation with capecitabine
(chemoradiation, i.e. chemotherapy as a radiosensitizer, capecit-
abine 2¥ 1000 mg/m2), followed by pre-operative chemotherapy
aimed at minimizing the likelihood of a (microscopically) positive
resection margin after resection of the primary tumour, according
to the national guidelines.23 In line with our institutional chemo-
therapy protocol, patients receive a total of six cycles. Moreover, in
our institution, patients with a locally advanced rectal carcinoma,
which was defined as a T4 tumour or a T3 tumour with involved
or threatened mesorectal fascia or an N2-status or a distally
located T3N1 tumour, receive chemoradiation followed by two
cycles of pre-operative full-strength chemotherapy (i.e. oxalipl-
atin, 130 mg/m2 with or without bevacizumab 7.5 mg/kg).
Patients with a non-locally advanced rectum carcinoma are gen-
erally treated with a short course of radiation therapy followed by
three cycles of pre-operative chemotherapy (i.e. oxaliplatin,
130 mg/m2 with or without bevacizumab 7.5 mg/kg). This also
allowed evaluation of the tumour response to chemotherapy. The
remaining cycles are generally administered either after liver
resection or after completion of the resection of the primary
tumour. Each deviation from this protocol only takes place after
careful and thorough evaluation at our weekly, institutional
multi-disciplinary meeting. Reasons for not completing all cycles
of chemotherapy are mainly patient based and include too severe
side-effects of pre-operative chemotherapy. However, rather than
treating all patients according to a strict and rigid protocol, we
intend to provide each patient with a tailor-made treatment
regimen.
After initial resectability of the CRLM was assessed based on the
criteria described above, all patients with a primary tumour
located in the rectum were considered for the liver-first approach,
whereas patients with a colorectal tumour located in the colon
were selected on a case-by-case basis in order to provide a tailor-
made management plan.
Data collection
Apart from standard demographic data (i.e. age and gender), the
following data were also collected for each patient: characteristics
of the primary tumour (i.e. location and size of the primary
lesions, TNM stage) as well as of the CRLM (i.e. distribution,
number and size of the lesions). Moreover, data concerning
treatment-related variables were collected (i.e. peri-operative
receipt of radiation and/or chemotherapy, details of the hepatic
surgery as well as data regarding the operation on the primary
tumour). Furthermore, data regarding post-operative outcome
(i.e. presence, type and severity of in-hospital or 90-day morbidity
and post-operative mortality within 90 days of treatment) and
data regarding disease recurrence and vital status were noted.
Disease recurrence was defined as a lesion that was a biopsy
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proven recurrent adenocarcinoma or a lesion that was deemed
suspicious on cross-sectional imaging in the setting of an elevated
carcinoembryonic antigen (CEA) level.
Statistical analyses
All statistical analyses were performed using SPSS version 17.0
(SPSS Inc., Chicago, IL, USA). Summary statistics were obtained
and presented as percentages or median values. Upon comparing
categorical data, the c2-test, or if deemed appropriate Fisher’s
exact test, was used, while the Mann–Whitney U-test was used to
compare continuous data. Recurrence-free and overall survival
analyses were performed using the non-parametric product
limit method.24 Overall, a P-value less than 0.05 was considered
significant.
Results
Patient and tumour characteristics
Between 1st January 2005 and 31st December 2010, 186 patients
underwent liver directed surgery for CRLM at our institution and
were queried from our hepatobiliary database. Specifically, 90
patients presented with synchronous CRLM and in 22 of these
patients (24.4%), a liver-first approach was planned during this
5-year period. These latter patients are the scope of the present
study. The characteristics of these patients are detailed in Table 1.
The site of the primary tumour was the rectum in most patients
(n = 19; 86.4%), whereas three patients (13.6%) had a carcinoma
located in the colon. The median pre-operative CEA level (range)
was 15.8 mg/L (1.90–321.0).
At the time of presentation, 15 patients (68.2%) complained of
primary tumour-associated symptoms. Furthermore, another two
patients (12.5%) developed symptoms caused by the primary
tumour during the course of their illness, but before their liver-
directed surgery. Both of these patients developed an obstruction
of the bowel as a result of their colorectal carcinoma and subse-
quently underwent a laparotomy during which a diverting ostomy
was constructed, before their liver-directed surgery.
Details of radiation and chemotherapeutic therapy
In total, 21 patients (95.5%) received radiation therapy of their
primary tumour. Eight patients (36.4%) received a short course of
radiation therapy, of whom seven patients (31.8%) also received
multiple cycles of pre-operative chemotherapy before surgery.
Moreover, 13 patients (59.1%) underwent a long course of radio-
therapy with a chemo-sensitizer (chemo-radiation therapy). Nine
of these patients (40.9%) received additional cycles of pre-
operative systemic chemotherapy (i.e. not as chemo-sensitizer).
Furthermore, one patient (4.5%) did not receive radiation therapy
of the primary tumour, but this patient did receive pre-operative
chemotherapy. All of the patients who received pre-operative che-
motherapy received an oxaliplatin-based chemotherapy regimen.
Moreover, the majority of patients (n = 10) received one or more
cycles including biologicals (i.e. bevacizumab).
Four patients (18.2%) received interval chemotherapy in the
surgical window between hepatic and colorectal surgery, exclud-
ing those patients who did not undergo resection of their primary.
Nine patients (40.9%) who completed the curative intent treat-
ment plan received adjuvant chemotherapy after completion of
both operations. For those patients who received chemotherapy
after their liver resection (either interval of adjuvant), this gener-
ally also consisted of an oxaliplatin-based regimen.
Details of surgery
Of the 22 patients in whom a liver-first approach was planned, in
one patient (4.5%) no liver resection was performed owing to a
per-operative diagnosis of locoregional perihilar lymph nodal
disease. These lymph nodes were located adjacent to the vena cava,
making performance of a lymphadenectomy impossible. The
operative characteristics of the 21 patients who did undergo a liver
Table 1 Patients and tumour characteristics
Variable No. of patients
(%), n = 22
Patient characteristics
Median age [range], year 65 [41–86]
Sex (male) 16 (72.7)
Median pre-operative CEA level [range], mg/L 15.8 [1.90–321.0]
Primary tumour site
Location of the primary tumour
Colon 3 (13.6)
Rectum 19 (86.4)
Symptoms caused by the primary tumour
Symptoms at the time of presentation
None 7 (31.8)
Rectal blood loss 9 (40.9)
Changes in bowel habits 4 (18.2)
Bowel obstruction 3 (13.6)
Onset of symptoms during the course of
the illness
None 5 (22.7)
Bowel obstruction 2 (9.1)
AJCC T-stage on pathologya
ypT1/ypT2 2 (12.5)
ypT3/ypT4 14 (87.5)




Size of largest metastasis (median [range]), cm 1.7 [0.4–6.6]
No. of metastasis (median [range]) 2 [1–7]
Location (unilobular) 10 (45.5)
aExcluding patients who did not undergo resection of their primary
colorectal tumor (n = 6).
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resection are detailed in Table 2. Importantly, one patient (4.5%)
underwent a planned two-stage approach for his bilateral CRLM.
This patient also underwent portal vein ligation (PVL) of the right
portal vein during the first stage of his treatment.
After a median interval of 3 months (range: 1–11), 16 patients
(72.7%) underwent surgery for their primary tumour. The opera-
tive characteristics of these 16 patients are detailed in Table 2. Of
the five patients who did not undergo surgery of their primary
tumour, three patients (13.6%) developed extensive metastatic
disease and were therefore not thought to be candidates for resec-
tion. Specifically, in two of these latter patients, the extrahepatic
metastases were diagnosed during attempted colorectal resection.
Furthermore, in two patients (9.1%) the primary tumour had
disappeared as a result of the chemo-radiation therapy and there-
fore in these patients a wait-and-see approach was conducted, in
accordance with a watchful wait protocol currently executed at
our institution. A complete response of the primary tumour was
diagnosed by endoscopic examination and was pathologically
confirmed by a biopsy of the region of the lesion. Altogether, the
total number of patients not treated according to the protocol was
four (18.2%), whereby excluding the two patients who are pres-
ently included in the follow-up protocol for complete responders
to chemo-radiation. (Fig. 1)
Upon comparing patients who completed their per-protocol
treatment and patients who deviated from the protocol, no differ-
ences were observed with regard to the location of the primary
tumour, size and the number of CRLM or the distribution of the
lesions (all P > 0.05). Moreover, there was no statistically signifi-
cant difference in the likelihood of succeeding between patients
who had a symptomatic primary lesion and patients who did not
(P = 0.63).
Pathological characteristics
The median number of CRLM resected was 2 (range: 1–7), with a
median size of the largest lesion of 1.7 cm (range: 0.4–6.6). On
final pathological analysis, 20 patients (95.2%) had negative
hepatic margins (R0).25 Moreover, in one patient (4.8%), no viable
tumour was found.
Excluding patients who did not undergo resection of their
primary colorectal tumour and therefore did not have pathologi-
cal staging of their primary tumour, most patients (n = 14; 87.5%)
had a ypT3 (i.e. invasion through the muscularis propria into
pericolorectal tissues) or a ypT4 (i.e. direct invasion in adjacent
organs or structures) primary tumour.26 Six patients (37.5%) were
found to have positive lymph nodes, therefore 10 patients (62.5%)
had node negative disease however all in the setting of pre-
operative chemotherapy (ypN0).
Post-operative and oncological outcome
The complication rate during hospital admittance after liver-
directed surgery, or the 90-day post-operative period, was 27.3%
(n = 6), all of which were major complications (Clavien grade
3).27 The specifics of post-operative morbidity are detailed in
Table 3. Importantly, there was no significant difference in the
interval between hepatic surgery and the resection of the primary
tumour when patients who did develop complications [median:
3.4 months (range: 3.3–9.8)] were compared with patients who
did not [median: 2.3 months (range: 1.0–10.9)] (P = 0.095). More-
over, eight patients (44.4%) developed post-operative complica-
tions after (attempted) resection of their primary tumour (n =
18), of whom half (n = 4; 22.2%) had also previously developed
post-operative morbidity after liver-directed surgery. While two
patients (11.1%) developed minor complications (Clavien grade
<3), six patients (33.3%) developed major complications (Clavien
grade3).27 Importantly, one patient (5.4%) died within 90 days
of operation for the primary tumour, on post-operative day 74.
At the time of last follow-up, one-third (n = 6; 33.3%) of the
patients who underwent the complete curative paradigm or in
whom a wait-and-see approach was conducted had developed
recurrent disease. Specifically, none of the two patients in whom a
wait-and-see approach was conducted experienced a local recur-
rence. The median recurrence-free survival after hepatic surgery
was 14.5 months. The pattern of recurrence was combined intra-
and extrahepatic recurrence in four patients (25.0%), whereas
another two patients (12.5%) developed recurrent disease outside
of the liver only. No patient developed recurrent disease solely in
Table 2 Details of surgical procedures
Variable No. of patients
(%), n = 22





Plus additional minor resection 4 (18.2)
Central hepatectomy 1 (4.5)
Two-stage resection
Triple metastasectomy and subsequent
hemihepatectomy
1 (4.5)
Type of colorectal resection
None 6 (27.3)
Watchful wait 2 (9.1)
Extensive metastatic disease 4 (18.2)
Transanal endoscopic microsurgery 1 (4.5)
Low anterior resection 9 (40.9)
With diverting ostomy 6 (27.3)
Hartmann’s resection 2 (9.1)
With revision ostomy 1 (4.5)
Right hemicolectomy 1 (4.5)
Rectum extirpation with end ostomy 2 (9.1)
Rectosigmoid resection with end ostomy 1 (4.5)
Median of lymph nodes harvested [range] 12 [4–14]
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the liver. On an intention-to-treat basis, the estimated overall 1-
and 3-year survival calculated from the time of liver surgery were
74.2% and 41.1%, respectively, with a median survival of 35.5
months. (Fig. 2)
Discussion
Based on serious potential pitfalls of the traditional approach for
synchronous CRLM, it has been proposed to reverse the order of
the staged approach for these patients i.e. the liver-first approach.
However, most data on this sequential in the treatment of patients
with CRLM comes from a small series. Mortensen et al.28
described 26 patients in whom the CRLM were resected before the
primary tumour. However, in only a small portion of these
patients, this therapeutic sequence was a planned strategy. Mentha
et al.12,17 have reported on their experience on several occasions
with the largest series including 35 patients, whereas Verhoef
et al.18 reported on 23 patients in whom a liver-first approach was
planned. Moreover, this latter group reported on a cohort of 20
patients who all completed their liver-first strategy within a larger
study on patients with synchronous CRLM.29 Nonetheless, in this
previous study, the specific characteristics of these 20 patients
were not described in great detail.
As previously mentioned, our institution has adopted the liver-
first strategy several years ago, particularly in all patients who
present with synchronous CRLM from a rectal origin but also in
selected patients with synchronous CRLM from a primary
tumour located in the colon, when an indication for pre-operative
radiation therapy or chemotherapeutic regimens is present. In the
current series, we report on 22 patients who were planned to
undergo a liver-first approach during the 5 years of inclusion.
Specifically, 18 patients (81.8%) were treated per protocol and
completed the treatment plan for liver and primary tumours. This
percentage of feasibility is higher than the rate of patients who
completed the formalized treatment plan reported by Verhoef
et al. (69.6%).18 Moreover, in the most recent series by Mentha
et al.12 the authors report that 14% of patients did not complete
the curative paradigm, while an additional 20% of patients had
their primary tumour removed at the same time as the hepatic
resection (i.e. a simultaneous approach). Therefore, in this previ-
ous study, merely 66% of patients were treated according to pro-
tocol. The feasibility of being able to complete the entire treatment
protocol under the liver-first approach has been of some concern.
As it has been stated that surgical management of CRLM is asso-
ciated with an increased quality of life compared with chemo-
therapeutic therapy alone,30 an aggressive approach seems
warranted. In our cohort about one-fifth of patients were unable
to complete their treatment paradigm, as four patients (18.2%)
deviated from the protocol as a result of the development of
extrahepatic disease during the course of their treatment (i.e.
under chemotherapy). It has been shown that tumour progression
of CRLM under pre-operative chemotherapy is associated with a
poor outcome, even after all (visible) metastatic disease is com-






























Figure 1 Flow chart of the 22 patients included in the present study. CRLM, colorectal liver metastasis; CS, chemo-sensitizer
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the potential benefit of the surgery-free interval as patients can be
‘saved’ an operation in the case of disease progression.
In two patients (9.1%), a complete response of the primary
lesion owing to radiation therapy was observed. While the disap-
pearance of the primary lesion has been shown to be of concern,
with adequate follow-up and strict surveillance including regular
evaluation of the CEA-level and appropriate cross-sectional
imaging, patients can still be treated under a curative paradigm.31
Therefore, these patients were not classified as treatment failures
in the present study. Furthermore, although obstruction by the
primary tumour during the course of treatment occurred in five
patients (22.7%), in all of these a diverting ostomy was con-
structed and in none of these patients this was a reason to divert
from the planned strategy.
On another note, the potential surgical morbidity in manag-
ing patients with synchronous CRLM has also been an area of
ongoing concern. Specifically, under the liver-first protocol, a
complication after hepatic resection can result in a delay with
regard to the treatment of the primary tumour. In our series, six
patients (27.3%) developed complications after liver-directed
surgery, whereas the post-operative mortality was zero. These
numbers corroborate the incidence of post-operative morbidity
reported in other, larger series.32,33 Importantly, the interval
between the operations for the hepatic and primary disease was
similar for patients who did and patients who did not develop
complications after liver surgery. Moreover, for patients in whom
a too small future remnant is anticipated and who are therefore
at an increased risk of developing hepatic failure, portal vein
embolization (PVE) or PVL could be undertaken to enlarge the
future liver remnant by means of hypertrophy,34,35 especially as
patients treated with the liver-first approach are generally
regarded to have advanced disease and undergo several cycles of
pre-operative chemotherapy which could have subsequently
caused hepatocyte damage. After surgery on the primary
tumour (n = 18), post-operative morbidity occurred in eight
patient (44.4%). Notably, one patient (5.6%) died during
the 90-day post-operative period. These complication rates
are similar to the post-operative morbidity rates reported in
cohorts of patients who had not previously undergone a liver
resection.36,37
Apart from the short-term results of the liver-first approach, it
is important to also emphasize the influence on long-term out-
comes (i.e. recurrence and survival) in these patients. In the
current series, on an intention-to-treat basis, the estimated
overall 1- and 3-year survival calculated from the time of liver
surgery were 74.2% and 41.1%, respectively, with a median sur-
vival of 35.5 months. These statistics are corroborated by other,
albeit limited, series on patients operated for synchronous
CRLM, treated using the traditional approach3,38 or the liver-first
strategy.12 However, owing to advances in medical oncology (e.g.
modern chemotherapy regimens)39,40 as well as surgical oncology
(e.g. performance of repeat resections41 and improved peri-
operative outcome),42 the overall survival for all patients who
Table 3 Specifics of direct post-operative outcomes
Variable No. of patients
(%), n = 22
Liver-directed surgery
Post-operative complications (any) 6 (27.3)
Minor (Clavien grade < 3) 0
Major (Clavien grade  3) 6 (27.3)
Post-operative mortality (within 90 days) 0
Specific complications
Biloma 3 (13.6)
Intra-abdominal abscess 1 (4.5)
Iatrogenic bowel perforation 1 (4.5)
Stroke 1 (4.5)
Surgery on primary colorectal tumoura
Post-operative complications (any) 8 (44.4)
Minor (Clavien grade < 3) 2 (11.1)
Major (Clavien grade  3) 6 (33.3)
Post-operative mortality (within 90 days) 1 (5.6)
Specific complications
Intra-abdominal abscess 4 (22.2)
Anastomotic leakage 1 (5.6)
Re-bleeding 1 (5.6)
Pneumonia 2 (11.1)
Fascia dehiscence 1 (5.6)
Urinary tract infection 1 (5.6)
Surgical site infection 1 (5.6)
aExcluding patients in whom no resection for a primary tumour was




























Figure 2 Kaplan–Meier curve showing overall survival of the 22
patients who were planned to undergo the liver-first approach
(intention-to-treat analysis)
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present with CRLM has improved dramatically. Therefore, it has
become increasingly important to assess disease recurrence in
order to draw conclusions with regard to the curative potential
of the proposed treatment paradigm. In the current cohort, six
(33.3%) of the patients who were treated per-protocol had
developed recurrent disease at the time of the last follow-up.
Available data on recurrence after the liver-first approach are
scarce and range from 25.0%18 to 66.7%12 at the time of the last
follow-up. However, as recurrence is associated with time passed
since surgery, it is preferred to investigate this variable in a time-
to-event modus rather that comparing the crude probabilities. In
the present cohort, we found a median recurrence-free interval
of 14.5 months. While other studies on the liver-first approach
did not report a median recurrence-free interval, this interval is
in concordance with those reported in assorted cohorts of
patients with CRLM.43,44 Moreover, although the recurrence rates
reported in the series on the liver-first approach varied greatly,
they do show that disease recurrence is not uncommon and
therefore, especially in the proposed treatment sequence, there
seems to be a role for a multidisciplinary approach.
The present study has several limitations associated with the
retrospective nature of the study. This limited number of patients
reflects the highly selected nature of the cohort of patients with
synchronous CRLM who were considered for this comparatively
novel approach. As a result of the small sample size, the study has
limited statistical power and therefore the statistical analyses are
also limited.
In conclusion, the present study shows that resection of hepatic
metastasis before resection of the primary colorectal tumour can
be performed with acceptable peri-operative mortality and mor-
bidity rates, similar to the traditional treatment paradigm for
synchronous CRLM. Especially when the primary tumour
requires a neo-adjuvant treatment strategy that provides a
window for the liver-first approach, this sequence of therapy
should be considered. Although over one-fifth of patients were
not able to complete the entire treatment plan, an important
finding of this series is that the anticipated pitfalls of this approach
(i.e. growth of CRLM beyond resectability and bowel obstruction
by the primary tumour) were not found to alter the proposed
treatment strategy. Moreover, the here presented data show that
patients with synchronous CRLM treated with the liver-first strat-
egy derive a considerable overall-survival benefit, although
disease-recurrence rates remain relatively high. Especially in light
hereof, the selection of patients for this novel strategy should be
individualized and incorporated in a multidisciplinary approach
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